Phase II study of amonafide in gastric adenocarcinoma. An Illinois Cancer Center trial

• Published in: Investigational new drugs Vol. 12; no. 3; p. 267
• Main Authors: Mullane, M R, Schilsky, R L, Carroll, R B, Wade, 3rd, J L, Kilton, L J, Blough, R R, Bauman, A, French, S L, Benson, 3rd, A B
• Format: Journal Article
• Language: English
• Published: United States 01.01.1994
• Subjects: Adenocarcinoma - drug therapy; Antineoplastic Agents - therapeutic use; Female; Hematologic Diseases - chemically induced; Humans; Imides - adverse effects; Imides - therapeutic use; Isoquinolines - adverse effects; Isoquinolines - therapeutic use; Male; Naphthalimides; Stomach Neoplasms - drug therapy
• ISSN: 0167-6997
• DOI: 10.1007/BF00873971

Twelve patients with recurrent, metastatic, or inoperable gastric adenocarcinoma were enrolled in an Illinois Cancer Center phase II trial of amonafide (nafidimide), a novel compound that acts as a DNA intercalator. Treatment consisted of a 60-minute infusion of amonafide which was administered daily for 5 consecutive days every 3 weeks at a starting dose of 300 mg/m2/d. Doses were modified according to the grade of toxicity experienced and eight patients underwent dose escalations. All 12 patients were evaluable for response and toxicities were predominantly hematologic. Stabilization of disease for at least 28 days was observed in seven patients and disease progression was noted in five. The median survival was 7.4 months. Doses were sufficient to produce severe bone marrow toxicity in one-third of the patients treated. None of the patients responded to therapy, implying a true response rate less than .221. Based on the results of this study, amonafide showed no activity against gastric adenocarcinoma; however toxicity appeared acceptable at the 300 mg/m2/d x 5 consecutive days every 3 weeks dose and schedule.